Genetically modified cells comprising a heterologous nucleic acid molecule inserted at a CD5 gene locus field

By inserting heterologous nucleic acid molecules at the CD5 gene locus in immune cells using CRISPR/Cas9, the method addresses the risk of unwanted properties and enhances cancer treatment effectiveness by reducing CD5 expression and facilitating the expression of therapeutic molecules in immune cells.

WO2024243436A2PCT designated stage expired Publication Date: 2024-11-28VITTORIA BIOTHERAPEUTICS INC
View PDF -1 Cites -1 Cited by

Patent Information

Application Number
PCT/US2024/030831
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-23
Filing Date
2024-05-23
Publication Date
2024-11-28

Smart Images

  • Figure US2024030831_28112024_PF_FP_ABST
    Figure US2024030831_28112024_PF_FP_ABST
Patent Text Reader

Abstract

The embodiments provide cells comprising a heterologous nucleic acid molecule inserted at a CD5 gene locus. Also provided herein are compositions comprising said cells, and methods of making and using said cells and compositions.
Need to check novelty before this filing date? Find Prior Art